Correlation Between Oncology Pharma and Sonnet Biotherapeutics

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Oncology Pharma and Sonnet Biotherapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Oncology Pharma and Sonnet Biotherapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Oncology Pharma and Sonnet Biotherapeutics Holdings, you can compare the effects of market volatilities on Oncology Pharma and Sonnet Biotherapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Oncology Pharma with a short position of Sonnet Biotherapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Oncology Pharma and Sonnet Biotherapeutics.

Diversification Opportunities for Oncology Pharma and Sonnet Biotherapeutics

0.28
  Correlation Coefficient

Modest diversification

The 3 months correlation between Oncology and Sonnet is 0.28. Overlapping area represents the amount of risk that can be diversified away by holding Oncology Pharma and Sonnet Biotherapeutics Holding in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Sonnet Biotherapeutics and Oncology Pharma is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Oncology Pharma are associated (or correlated) with Sonnet Biotherapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Sonnet Biotherapeutics has no effect on the direction of Oncology Pharma i.e., Oncology Pharma and Sonnet Biotherapeutics go up and down completely randomly.

Pair Corralation between Oncology Pharma and Sonnet Biotherapeutics

Given the investment horizon of 90 days Oncology Pharma is expected to generate 45.86 times more return on investment than Sonnet Biotherapeutics. However, Oncology Pharma is 45.86 times more volatile than Sonnet Biotherapeutics Holdings. It trades about 0.36 of its potential returns per unit of risk. Sonnet Biotherapeutics Holdings is currently generating about -0.21 per unit of risk. If you would invest  0.00  in Oncology Pharma on September 13, 2024 and sell it today you would earn a total of  0.01  from holding Oncology Pharma or generate 9.223372036854776E16% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthVery Weak
Accuracy92.06%
ValuesDaily Returns

Oncology Pharma  vs.  Sonnet Biotherapeutics Holding

 Performance 
       Timeline  
Oncology Pharma 

Risk-Adjusted Performance

27 of 100

 
Weak
 
Strong
Strong
Compared to the overall equity markets, risk-adjusted returns on investments in Oncology Pharma are ranked lower than 27 (%) of all global equities and portfolios over the last 90 days. Despite fairly weak basic indicators, Oncology Pharma demonstrated solid returns over the last few months and may actually be approaching a breakup point.
Sonnet Biotherapeutics 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Sonnet Biotherapeutics Holdings has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of inconsistent performance in the last few months, the Stock's basic indicators remain very healthy which may send shares a bit higher in January 2025. The recent disarray may also be a sign of long period up-swing for the firm investors.

Oncology Pharma and Sonnet Biotherapeutics Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Oncology Pharma and Sonnet Biotherapeutics

The main advantage of trading using opposite Oncology Pharma and Sonnet Biotherapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Oncology Pharma position performs unexpectedly, Sonnet Biotherapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Sonnet Biotherapeutics will offset losses from the drop in Sonnet Biotherapeutics' long position.
The idea behind Oncology Pharma and Sonnet Biotherapeutics Holdings pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.

Other Complementary Tools

Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities